Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Pharmacodynamics
- Sponsors The Medicines Company
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2013 New trial record